Background
Chronic kidney disease (CKD) is a major and serious global health burden that leads to kidney failure as well as systemic diseases. Gut dysbiosis-a change in the microbial diversity in the gut-has been observed in CKD patients [
1]. Likely, many studies have suggested that the microbiome in the oral cavity also plays an important role in the health of the host [
2], and the association between the oral microbiome and CKD pathogenesis has been addressed. For example, Hu J et al. found that enrichment of
Neisseria accompanied by depletion of
Veillonella and
Streptococcus in CKD patients [
3]. Moreover, they detected a negative association between
Neisseria and
Streptococcus with the estimated glomerular filtration rate (eGFR) [
3]. Duan X et al. reported that end-stage renal disease changeed the salivary microbiome in CKD patients, and it was associated with oral health state [
4]. Notably, the periodontal pathogens were enriched in CKD patients undergoing hemodialysis [
4]. Guo S et al. found that oral microbial diversity in CKD patients was increased.
Streptococcus,
Actinomyces, and
Leptotrichia were enriched in CKD patients, while
Prevotella and
Haemophilus were decreased in CKD patients [
5].
The potential impact of salivary microbiome on diabetes has been demonstrated in recent years. Several studies compared the salivary microbiome in patients with diabetes to that of healthy subjects using next generation sequence. Data showed that diabetes was associated with a decrease in bacterial diversity of the salivary microbiome [
6‐
8]. In addition, higher salivary levels of
P. gingivalis,
T. forsythia, and
F. alocis were reported in patients with gestational diabetes [
9]. Although diabetic kidney disease develops in approximately 40% of patients who are diabetic and is the leading cause of CKD worldwide [
10], and the association between the gut microbiome and diabetes has been extensively explored [
11‐
13], few studies have reported the impact of the salivary microbiome on CKD patients complicated with diabetes.
As approximately 50% of adults had hypertension [
14], the pathological role of the microbiome in hypertension, including the salivary microbiome, has gained increasing attention. Barbadoro P. et al. reported that bacterial species of dental pathologies, such as
Actinobacillus actinomycetemcomitans had a higher concentration in an oral plaque of hypertension patients [
15]. Gordon JH found that
Prevotella oral and
Streptococcus oralis increased in hypertension women taking antihypertension medications compared to those with normal blood pressure [
16]. However, until now, the alteration of the salivary microbiome in hypertension patients with kidney damages has not been reported.
The kidneys are a frequent target of systemic immune and autoimmune disorders, including systemic autoimmunity and vasculitis, immune complex-related serum sickness, and complement disorders [
17]. The human microbiome is responsible for interfacing with the induction, development, and modulation of immune responses [
18]. Therefore, there might be biological interconnectivity of salivary microbiome and immunological profiles in CKD patients.
Here, we hypothesize that patients with CKD have a different microbial profile in saliva compared with healthy controls (HC). This deviation in the microbiome has a potential role in the etiology of the common diseases of diabetes and hypertension in CKD and the outcomes of their immunity.
Discussion
Following a large number of studies on the human gut microbiome in an unhealthy state, the role of the salivary microbiome in health has been gradually explored [
2]. As a study that is not evenly matched with age-gender-BMI between cases and controls, confound microbiome analyses can produce spurious microbial associations with human diseases [
22], we performed an age-gender-BMI matched case–control study to examine the salivary microbiome in non-dialysis CKD patients. In addition, our present study assessed the associations of co-occurrence of diabetes and hypertension and immunity which has been rarely reported.
We observed a distinct bacterial community in the saliva of CKD patients. Such an alteration in CKD patients was also reported by previous studies [
3,
5]. In addition, we noticed that no bacterial richness and diversity changes were observed in CKD patients, which were dissimilar to previous studies [
4]. A higher level of bacterial diversity in CKD patients’ saliva has been reported by both Duan X et al. and Guo S. et al. on the Chinese population [
4,
5]. However, no consistent findings of alteration trend in bacterial richness in CKD patients were demonstrated by their studies. Based on the two previous studies and our present study, it is hard to conclude that there is an association between bacterial richness and diversity in the salivary microbiome in the Chinese CKD population.
As diabetes and hypertension play vital importance in the progression of kidney damage [
23], we assessed the salivary microbiome in CKD patients with and without diabetes/hypertension. Although both of DM/HTN-CKD and nonDM/HTN-CKD patients demonstrated a different bacterial community and bacterial diversity from those in the controls, no differences were observed between those with and without complications of diabetes/hypertension. A similar finding was reported by a human gut microbiome study [
24]. In their study, Tao S et al. also noticed that there was no difference between CKD patients with and without diabetes in their microbial community and diversity [
24]. Under this perspective, although the relationship between kidney damage and salivary microbiome can be defined, the specific contributors of diabetic and hypertensive nephropathy for the profile of microbiome should be explored using more clinical and animal studies.
It is worthy to note, although the ASOPOS-CKD and ASONEG-CKD patients did not show difference in the bacterial community, the ASONEG-CKD patients had higher bacterial richness than the ASOPOS-CKD patients. The association between the salivary microbiome and anti-streptolysin O has never been reported, whereas its association with the gut microbiome revealed a negative correlation with
Lactobacillus the concentration of anti-streptolysin O titer [
25], which indicates that positive ASO suppresses the growth of probiotic bacteria, such as
Lactobacillus.
There were several bacterial taxa exhibiting alterations that have never been reported by previous salivary studies on CKD, such as bacterial phylum Actinobacteria and its genus
Actinomyces sharply depleted in CKD patients. This finding is not consistent with Guo S. et al. report. In their study,
Actinomyces increased in the CKD group [
5].
Prevotella, as one of the major bacterial genera in the oral microbiome [
26], is depleted in CKD patients. Comparisons of bacterial genus among the three groups of HTN-CKD, nonHTN-CKD, and HC demonstrated that
Prevotella 7 plays a role in CKD, regardless of the complication of hypertension.
Prevotella spp., a proteolytic/amino acid–degrading bacteria, can break down proteins and peptides into amino acids and degrade them further via specific pathways to produce short-chain fatty acids [
27], and its species are considered commensal microbes in the oral cavity [
28]. However, several recent studies demonstrated that
Prevotella is associated with diseases, such as periapical infection [
29], gout [
30], and multiple sclerosis [
31]. Thus, although
Prevotella declined in CKD patients which included those with and without hypertension, its role needs further investigation by salivary microbiome transplantation in CKD patients and animal models.
The enrichment of
Pseudomonas in CKD patients is outstanding in our present study, as it was confirmed by Wilcoxon signed-rank test, ROC curve, and LefSe analysis. In addition, the abundance of
Pseudomonas declined in both the CKD patients complicated with and without hypertension when compared to controls. We noticed that the level of immunoglobulin G (IgG) antibody was negatively associated with the abundance of
Pseudomonas. IgG is a major component of humoral immunity [
32]. According to data from the literature, lower serum IgG level has been associated with a higher proportion of chronic pathological changes, lower eGFR, and poor renal outcome [
33]. The negative association between Ig G and
Pseudomonas indicates that the salivary microbiome plays a role in regulating CKD patients’ immunity.
We observed that
Lautropia increased in CKD patients. Enrichment of salivary
Lautropia might indicate an unhealthy state in the human oral cavity, as several previous studies demonstrated that
Lautropia increased in various diseases. For example, Yu F and his group reported that oral lichen planus patients with erosive lesions had a higher level of
Lautropia than those without erosive lesions and healthy subjects [
34]. Snider E J et al. found that
Lautropia can be listed as a diagnostic biomarker for patients with Barrett’s esophagus [
35]. Also, Li D et al. reported that
Lautropia could be used for the diagnosis of hepatitis B patients [
36].
The depletion of
Trichococcus in CKD patients might be associated with an unhealthy state in the oral cavity. A previous study also demonstrated a decrease of
Trichococcus in pediatric patients with obstructive sleep apnea [
37]. A further investigation of the function of
Trichococcus using animal models is necessary.
When comparing the metabolic pathway data of the salivary microbiome, we found several metabolic pathways were associated with CKD. The upregulation of the pathway of lipid metabolism is inconsistent with a previous oral study on CKD patients [
3], while the downregulation of metabolism of cofactors and vitamins is similar to a gut study on CKD [
38]. A further study using metabolome identification is needed for exploring the metabolism in CKD and its association with salivary microbiome.
Like previous studies on the human salivary microbiome[
4,
5], our present study again demonstrated that CKD patients had a distinct microbiome from controls. However, the complications of diabetes and hypertension act out in the microbial community in CKD patients. As saliva is a diagnostic fluid with easy and non-invasive collection, the potential value of
Pseudomonas as a biomarker of CKD in saliva suggests that we should make detailed investigations in clinical settings.
Although therapeutic interventions aimed at restoring bacterial flora in the saliva in CKD patients may be future targets, current salivary microbiome study in a single-center is limited, necessitating further research. Further multi-center studies correlating the salivary microbiome with the gut microbiome, intestinal permeability markers, inflammatory markers, epigenetic factors, and various etiologies of CKD are needed to better interpret the salivary microbiome as a potential diagnostic biomarker and to investigate the diagnostic value and therapeutic effect in CKD patients. When the diagnostic value is confirmed by several large and multi-center studies, salivary microbiome transplantation should be investigated to replace the treatment option of fecal microbiome transplantation for CKD. As saliva is more easily collected using sterile collection tubes from healthy donors comparing to fecal samples.
Our present study has some limitations. First, only local community participants were involved in this study. Human microbiome studies demonstrated that sampling a broad population of humans representing different cultural traditions offers an opportunity to discover how our microbiomes vary between populations [
39]. Thus, multicenter studies in geographically distinct areas with more study participants, as well as longitudinal study designs that consider individual differences in the salivary microbiomes of CKD individuals, are essential for a dysbiosis of this prevalence. Second, although it seems that the complications of diabetes and hypertension were not associated with the alteration of salivary microbiome in CKD patients, the sample size in the subgroups of DM-CKD/HTN-CKD and nonDM-CKD/nonHTN-CKD were too small and unequal, which might lead to statistical bias. A further study with larger and equal sample size design is necessary to re-assess the findings of the present study.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.